UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2025, AND DECEMBER 31, 2024, AND FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
99.2
OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE NINE MONTHS ENDED SEPTEMBER 30, 2025 AND 2024
99.3
DIAMIR BIOSCIENCES CORP.'S UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF NOVEMBER 30, 2025 AND MAY 31, 2025, AND FOR THE SIX MONTHS ENDED NOVEMBER 30, 2025 AND 2024
99.4
DIAMIR BIOSCIENCES CORP.'S OPERATING AND FINANCIAL REVIEW AND PROSPECTS IN CONNECTION WITH THE UNAUDITED INTERIM CONSOLIDATED FINANCIAL STATEMENTS FOR THE SIX MONTHS ENDED NOVEMBER 30, 2025 AND 2024
99.5
UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL STATEMENTS